LOGIN  |  REGISTER
Compass Therapeutics

Bio-Rad Laboratories' Management to Participate in Upcoming Investor Conferences

August 25, 2025 | Last Trade: US$286.49 6.20 2.21

HERCULES, Calif. / Aug 25, 2025 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the company’s executive leadership team will participate in the following upcoming investor conferences:

2025 Wells Fargo Healthcare Conference

Format: Fireside chat and one-on-one investor meetings
Participants: Norman Schwartz, Chairman and Chief Executive Officer, Roop K. Lakkaraju, Chief Financial Officer
Date and Time: Thursday, September 4, 2025, at 12:45 PM Eastern Time (9:45 AM Pacific Time); a live webcast and subsequent replay of the fireside chat event will be available in the Investor Relations section of Bio-Rad’s website at bio-rad.com

Morgan Stanley 23rd Annual Global Healthcare Conference

Format: One-on-one investor meetings
Participants: Roop K. Lakkaraju, Chief Financial Officer
Date: Tuesday, September 9, 2025

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page